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Abstract
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Pseudomonas aeruginosa histidyl-tRNA synthetase (HisRS) was selected as a target for antibiotic
drug development. The HisRS protein was overexpressed in Escherichia coli and kinetically
evaluated. The KM values for interaction of HisRS with its three substrates, histidine, ATP, and
tRNAHis, were 37.6, 298.5, and 1.5 µM, while the turnover numbers were 8.32, 16.8, and 0.57 s−1,
respectively. A robust screening assay was developed, and 800 natural products and 890 synthetic
compounds were screened for inhibition of activity. Fifteen compounds with inhibitory activity
were identified, and the minimum inhibitory concentration (MIC) was determined for each against
a panel of nine pathogenic bacteria. Each compound exhibited broad-spectrum activity. Based on
structural similarity and MIC results, four compounds, BT02C02, BT02D04, BT08E04, and
BT09C11, were selected for additional analysis. These compounds inhibited the activity of HisRS
with IC50 values of 4.4, 9.7, 14.1, and 11.3 µM, respectively. Time-kill studies indicated a
bacteriostatic mode of inhibition for each compound. BT02D04 and BT08E04 were
noncompetitive with both histidine and ATP, BT02C02 was competitive with histidine but
noncompetitive with ATP, and BT09C11 was uncompetitive with histidine and noncompetitive
with ATP. These compounds were not observed to be toxic to human cell cultures.

Keywords
histidyl-tRNA synthetase; drug discovery; tRNA aminoacylation; protein synthesis; Pseudomonas
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Introduction
Resistance to multiple antimicrobial agents in pathogenic bacteria is spreading throughout
the world and has become a serious problem that significantly threatens public health.1
These multi-drug-resistant (MDR) bacteria have negatively impacted the clinical setting,
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with increasing numbers of patients treated in hospitals for infection with drug-resistant
bacteria. In recent reports, the Infectious Disease Society of America (IDSA) has
summarized the current and future public health burden resulting from drug-resistant
bacteria, citing a current annual cost to the U.S. health care system for antibiotic-resistant
infections of as much as $34 billion and growing.2 Pseudomonas aeruginosa is an
opportunistic Gram-negative pathogen and a common cause of nosocomial infections, and
the leading cause of mortality in cystic fibrosis patients.3 This bacterium has the remarkable
ability to acquire resistance, intrinsic as well as acquired, against multiple groups of
antimicrobial agents, including β-lactams, aminoglycosides, and fluoroquinolones, and is
referred to as a member of the class of pathogens called “superbugs.”4 The drug-resistant
nature of these bacteria make treatment of infections both difficult and expensive and has
resulted in an unmet need for the development of new antimicrobial agents with distinctly
different modes of action than the current armament of antibiotics.
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Aminoacyl-tRNA synthetases (aaRSs) play a central role in protein biosynthesis by
catalyzing the covalent attachment of the amino acids to the cognate tRNA and are crucial
for cell growth and viability. Therefore, bacterial aaRS enzymes, which are very different at
the amino acid sequence level than their eukaryotic counterparts, are valid targets for
development of potential therapeutics.5 The aaRSs are evenly grouped into two different
classes, with each class containing 10 members. Class I aaRSs contain two consensus
sequences (HIGH and KMSKS) in their active site and bind ATP through a conserved
structural domain (the Rossman fold), while class II aaRSs contain three conserved
structural motifs (motifs I, II, and III) composing the ATP binding site.6 Both classes can be
further divided into a number of subclasses based on structural similarities, and within the
class II enzymes, there are three distinct subgroups. Subclass IIa enzymes are homodimers
and contain a C-terminal insertion that interacts with the tRNA, while in subclass IIb
enzymes, this insertion is located within the N-terminal. The subclass IIc enzymes are
tetramers, and tRNA binding elements appear to be less conserved than in the other class II
aaRSs.7 Histidyl-tRNA synthetase (HisRS) is a class IIa aaRS composed of three conserved
domains: the catalytic domain that resides in the N-terminal, the C-terminal domain that
harbors the tRNA anticodon binding site, and a HisRS unique insertion domain containing
50–75 residues forming an α-helix between motifs II and III.8 HisRS also contains two
additional unique motifs that facilitate histidine (His) binding: histidine A (HisA, RGLDYY)
and histidine B (HisB, GGRYDG). The HisA and HisB motifs are highly conserved among
all known HisRS enzymes.8–12 Upon His binding, the HisA motif is rearranged to increase
hydrogen bonding capabilities, and the shape and electrostatic complementarity of the
binding pocket. This results in a conformational change optimizing the amino acid binding
pocket specificity for His, thus enhancing fidelity.9
In this work, HisRS from P. aeruginosa was purified and enzymatically characterized by
measuring its kinetic parameters (KM, Vmax, and kcat) governing interactions with His, ATP,
and tRNAHis. It was then developed into a screening platform using scintillation proximity
assay (SPA) technology13 and used to screen 1690 natural and synthetic compounds. Four
compounds were identified as inhibitors of P. aeruginosa HisRS and characterized for
inhibitory activity and toxic potential to human cell cultures.
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Materials and Methods
Materials
Oligonucleotides were from Integrated DNA Technologies (Coralville, IA). All other
chemicals were from Fisher Scientific (Pittsburgh, PA). DNA sequencing was performed by
Functional Bioscience (Madison, WI). Radioactive isotopes were from PerkinElmer
(Waltham, MA). Escherichia coli tolC mutant, P. aeruginosa PAO200 (efflux pump mutant),
and P. aeruginosa hypersensitive strain (ATCC 35151) were a kind gift from Urs Ochsner
(Crestone Pharma, Boulder, CO). All other bacteria were from the American Type Culture
Collection (ATCC) (Manassas, VA). Penicillin-streptomycin solution was from Mediatech,
Inc. (Manassas, VA). The synthetic compound library was from TimTec LLC (Newark, DE),
and the natural compound library was from MicroSource Discovery Systems (Gaylordsville,
CT). All compounds were provided at or above 95% homogeneity.
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Gel Electrophoresis and Protein Analysis
Sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) was performed
using 4%–12% polyacrylamide precast gels (Novex NuPAGE; Invitrogen, Waltham, MA)
with MOPS running buffer (Invitrogen). EZ-Run Rec Protein Ladder was from Fisher
Scientific. Gels were stained with Simply Blue Safe Stain (Invitrogen). Protein
concentrations were determined by the method of Bradford14 using bovine serum albumin
(BSA) as the standard.
Cloning and Purification of P. aeruginosa HisRS

Author Manuscript

The genes encoding P. aeruginosa HisRS were amplified by PCR (Bio-Rad MJ Mini Thermo
Cycler, Hercules, CA) from P. aeruginosa PAO1 (ATCC 47085) genomic DNA using the
forward primer (5′-ATATGCTAGCAGCAAGTCCCTGCAAGCCA-3′) designed to add an
NheI restriction site to the 5′ end of the gene and the reverse primer (5′CATTGGATCCTCAAGCCTGTGCCAGACAGG-3′), which was designed to add a BamHI
restriction site to the 3′ end of the gene. The PCR product was inserted into a pET-28b(+)
plasmid (Novagen, Darmstadt, Germany) digested with NheI/BamHI. The recombinant
plasmid was transformed into E. coli Rosetta 2(DE3) Singles Competent Cells (Novagen).

Author Manuscript

Bacterial cultures were grown in terrific broth containing 25 µg/mL of kanamycin and 50
µg/mL of chloramphenicol at 37 °C, and the target protein was expressed at an optical
density (A600) of 0.6–0.8 by the addition of isopropyl β-D-1-thiogalactopyranoside (IPTG)
to 0.5 mM. Growth of bacterial cultures was continued for 3 h postinduction, and the
bacteria were harvested by centrifugation (10,000g, 30 min, 4 °C). Bacterial cells were lysed
and fraction I lysate was prepared as previously described.15 P. aeruginosa HisRS was
precipitated by the addition of ammonium sulfate (AS) to 60% saturation and further
purified to greater than 98% homogeneity using nickel-nitrilotriacetic acid (NTA) affinity
chromatography (Perfect Pro, 5 Prime), followed by dialysis (two times) against a buffer
containing 20 mM Hepes-KOH (pH 7.0), 40 mM KCl, 1 mM MgCl2, 0.1 mM EDTA, and
10% glycerol. Purified proteins were fast frozen by immersion in liquid nitrogen and stored
at −80 °C.
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ATP:PPi exchange reactions (100 µL) were carried out for 20 min at 37 °C in a buffer
containing 50 mM Tris-HCl (pH 7.5), 10 mM potassium fluoride (KF), 8 mM MgOAc, 1
mM dithiothreitol (DTT), 2 mM [32P]PPi (50 cpm/pmol), and 0.05 µM P. aeruginosa HisRS,
as described.16 In reactions in which the concentration of ATP was varied (100, 200, 300,
400, 500, and 750 µM), the His concentration remained constant at 2 mM; alternatively,
when the concentration of His was varied (3.12, 6.25, 12.5, 25, 50, 100, and 200 µM), the
ATP concentration was held constant at 2 mM. The exchange of PPi in these reactions was
measured between 1 and 5 min, and initial velocities for exchange of PPi were determined.
The data were fit to the Michaelis–Menten steady-state model using XLfit (IDBS, Alameda,
CA) and the KM, Vmax, and kcat for the interactions of P. aeruginosa HisRS with ATP and
His were determined.
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Aminoacylation Assays to Determine Kinetics
Aminoacylation was measured using filter binding assays (50 µL) containing 50 mM TrisHCl (pH 7.5), 7.5 mM MgCl2, 2.5 mM ATP, 1 mM DTT, 75 µM [14C] His, and 0.1 µM P.
aeruginosa HisRS, as previously described.13 The tRNAHis concentrations were 0.03, 0.6,
0.9, 1.2, 1.8, 2.4, 3, and 4.5 µM. Assays were stopped at time intervals between 1 and 5 min.
Initial velocities for tRNA aminoacylation were calculated for all concentrations, and the
data were fit to the Michaelis–Menten steady-state model using XLfit (IDBS) to determine
the KM, Vmax, and kcat values.
Chemical Compound Screening
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tRNA aminoacylation was monitored using a SPA, as previously described.16 The
concentration of P. aeruginosa HisRS in the screening assays was 0.2 µM. The screening
reactions were carried out in 96-well microtiter plates (Costar). Compounds were dissolved
in 100% DMSO, and the final concentration of compounds in the screening assay was 132
µM. Briefly, 2 µL of compound (3.3 mM) was equilibrated by the addition of 33 µL of the
protein/substrate mix described above for the aminoacylation assay (minus tRNA). Control
reactions contained only DMSO with no compound. This mixture was incubated at ambient
temperature for 15 min, and then reactions were started by the addition of 15 µL of E. coli
tRNA (80 µM total tRNA or 2.5 µM tRNAHis), followed by incubation for 30 min at 37 °C.
Reactions were stopped by the addition of 5 µL of 0.5 M EDTA. A total of 400 µg of yttrium
silicate (Ysi) poly-L-lysine-coated SPA beads (PerkinElmer) in 150 µL of 300 mM citric acid
was added and allowed to incubate at room temperature for 1 h. The plates were analyzed
using a 1450 Microbeta (Jet) liquid scintillation/luminescent counter (Wallac). To determine
IC50 values, the test compounds were serially diluted from 200 µM to 0.4 µM in the SPAbased aminoacylation assays. The IC50 values observed using SPA technology, for the four
compounds that were characterized, were confirmed using the filter binding assays described
above.
Microbiological Assays
Broth microdilution minimum inhibitory concentration (MIC) testing was performed in 96well microtiter plates according to Clinical Laboratory Standards Institute guideline M7-
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A7.17 MIC values were determined for E. coli (ATCC 25922), E. coli tolC mutant
(W4573:tolC::Tn10), Enterococcus faecalis (ATCC 29212), Haemophilus influenzae (ATCC
49766), P. aeruginosa (ATCC 47085), P. aeruginosa PAO200 (efflux pump mutant), P.
aeruginosa hypersensitive strain (ATCC 35151), Staphylococcus aureus (ATCC 29213), and
Streptococcus pneumonia (ATCC 49619).
Time-kill studies were performed according to the CLSI document M26-A18 using S. aureus
and the P. aeruginosa hypersensitive strain for compounds BT02D04, BT08E04, and
BT09C11, and S. aureus and H. influenzae for compound BT02C02 based on the MIC assay
results. Growth media was haemophilus test medium for H. influenzae and brain heart
infusion for P. aeruginosa and S. aureus (Becton, Dickinson and Company, Franklin Lakes,
NJ). The same growth media was used in MIC and time-kill studies.
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In Vitro Cytotoxicity Test
The toxic effect of each compound on the growth of human cell cultures was carried out as
described using human embryonic kidney 293 cells (HEK293).19 The Trevigen TACS MTT
Cell Proliferation Assay Kit (Gaithersburg, MD) was used to assess impacts on human cell
proliferation and/or viability. The MTT assays were carried out in triplicate at each
compound concentration. The concentration of hit compounds in assays ranged from 25 to
400 µg/mL, and the control staurosporine was serially diluted in assays from 1 to 0.001
µg/mL. Student’s two-tiered t test was utilized to assess statistical significance.
Binding Mode Assay

Author Manuscript

To determine if the hit compounds competed with either ATP or the amino acid for binding,
IC50 values were determined in aminoacylation assays as described.16 The P. aeruginosa
HisRS concentration was set at 0.1 µM. For competition with ATP, IC50 values were
determined in reactions containing varying ATP concentrations (25, 50, 100, 250, 500, and
1000 µM). To determine competition with His, the same assays were used with varying
concentrations of the amino acid (25, 50, 100, 200, and 300 µM). Compounds were serially
diluted in IC50 assays from 200 to 0.4 µM. Background amounts of free [14C]His in the
absence of HisRS were insignificant.

Results
Sequence Analysis

Author Manuscript

The crystal structures of three different bacterial forms of HisRS have been well defined: (1)
the structures in apo forms, from S. aureus9 and Thermus thermophilus (Tth);20 (2) the
structures from T. thermophilus,11,21 E. coli,12 and Burkholderia thailandensis22 in a
complex with His or tRNA; and (3) the structures from T. thermophilus11 and E. coli23 in a
complex with the intermediate histidyl-adenylate. When compared with the corresponding
enzymes from E. coli, S. aureus, or T. thermophilus (Fig. 1), the amino acid sequence
conservation of HisRS from P. aeruginosa is moderately similar, with similarities ranging
between 55% and 73% (Suppl. Table S1). However, when compared with human cytosolic
or mitochondrial HisRS (hcHisRS or hmHisRS), there is only 30% and 31% sequence
similarity, respectively.
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The His and ATP binding sites are primarily located in motifs II and III, which is the case
with all other class II aaRS enzymes. His binds in a deep pocket formed by two HisRSspecific peptides, HisA and HisB, which are highly conserved among all known HisRS
proteins.11 The His imidazole ring forms hydrogen bonds with Glu-130 and Tyr-264 (E. coli
numbering), and Tyr-264 also forms hydrogen bonds to Thr-85, Arg-259, and Tyr-288 to
maintain correct orientations for binding the amino acid.12 The α-amino group of His
interacts with both Thr-85 and Tyr-263, and stabilizes Glu-83 by hydrogen bond formation.
11,12 These residues are all identical in the four HisRS proteins analyzed (Fig. 1). The polar
pocket, together with the hydrogen bonds, excludes any hydrophobic amino acid from
binding.11

Author Manuscript

Unlike the strict conservation observed in the amino acids around the His binding site, the
amino acids forming the ATP binding pocket are more variable. The three phosphates of
ATP interact with the guanidinium groups of four arginine residues that are completely
conserved in HisRS from the aligned bacteria. The α-phosphate associates with Arg-113 and
Arg-259 (E. coli numbering), the β-phosphate interacts with Arg-113, and the γ-phosphate
makes contact with Arg-121 and Arg-311.12 The variation in conservation is seen in some of
the amino acids interacting with the ribose group of ATP. In E. coli HisRS, Gln-127,
Ala-335, Ser-336, and Gly-365 likely have interactions with the ribose.8 All four of these
amino acids are conserved in HisRS from E. coli and P. aeruginosa, but slight variations
occur at Ala-335, Ser-336, and Gly-365 in HisRS from S. aureus and T. thermophilus.

Author Manuscript

The tRNA binding regions are less conserved than either the His or the ATP binding sites.
The acceptor stem of tRNAHis is recognized by interaction of Arg-7, Arg71, Arg-115, and
Arg-122 (T. thermophilus numbering) with the tRNA G1 nucleotide; Glu-64, Glu-114
Gln-117, Lys-118, and Arg-120 with the tRNA C70-C72, C74, and A76 nucleotides; and
Arg197, Arg-204, and Lys-209 with the tRNA C2-C75 base pair; and Gly-260, Tyr-264, and
Ala-278 form nonspecific hydrogen bonds through their main chain amide nitrogens. The
absolutely conserved residues Glu-64 and Glu-114 are essential for aminoacylation.
However, the other residues contribute less to substrate recognition.21 The GUG/A triplet
anticodon forms specific hydrogen bonds with HisRS. tRNA G34 forms six hydrogen bonds
with Glu-386, Asp-387, and Glu-388; U35 forms three hydrogen bonds with Gln-404; and
G/A36 forms two hydrogen bonds with Lys-397 and Leu-399.21

Author Manuscript

Without the luxury of a crystal structure for P. aeruginosa HisRS, the conservation of the
amino acids observed in regions vital for interactions with the substrates when compared
with that of the homologs from E. coli, S. aureus, and T. thermophilus indicates that the
active sites are similarly constructed. This suggests that a compound that interferes with
activity by binding in or near these strategic regions may have broad-spectrum inhibitory
activity.
Protein Expression and Characterization
The gene encoding HisRS (hisS) from P. aeruginosa was cloned, expressed, and purified as
described in Materials and Methods. The purified protein was greater than 98%
homogeneous as visualized by SDS-PAGE (Suppl. Fig. S1). In aminoacylation assays, P.
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aeruginosa HisRS was shown to be active in attaching radiolabeled His to tRNAHis (Suppl.
Fig. 2A).
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The result of the aminoacylation reaction is the covalent attachment of a specific amino acid
to the cognate tRNA, and this process occurs via two steps. In the first step, the amino acid
and ATP are condensed, resulting in the formation of an aminoacyl-adenylate intermediate,
followed by the release of an inorganic pyrophosphate. This reaction is reversible with most
aaRS enzymes in the absence of a cognate tRNA, and the parameters governing the kinetic
interaction of the aaRS with the amino acid and ATP substrates may be determined. The
kinetic parameters KM, kcat, and kcat/KM for the interaction of HisRS with His and ATP have
been determined by measuring the initial rate of the ATP:PPi exchange during this reversible
reaction and fitting the data to the Michaelis–Menten steady-state model. To determine the
interaction of HisRS with the amino acid, the concentration of ATP was held constant (2
mM), while concentrations of His were varied (3–200 µM) (Fig. 2B). From these data, the
KM and kcat values for the interaction with His were calculated to be 37.6 µM and 8.32 s−1,
respectively (Fig. 2E). E. coli HisRS was previously shown to have a similar KM of 30 µM12
and a turnover of 7–142 s−1, as measured by different research groups.24,25 Alternatively, to
determine the kinetic parameters for the interaction with ATP, the concentration of ATP was
varied between 100 and 750 µM while maintaining a constant concentration of His (2 mM)
(Fig. 2C). The KM and kcat values for interaction with ATP were calculated to be 298.5 µM
and 16.8 s−1, respectively. This again is similar to the interaction observed with ATP for E.
coli HisRS, which has a reported KM of 890 µM12 and a kcat of 34 s−1.24
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The formation of an ester bond between the hydroxyl group of the 3′ terminal adenosine of
tRNA and the carboxylic acid function of the amino acid constitutes the second step in the
aminoacylation process. The ability of P. aeruginosa HisRS to aminoacylate tRNAHis was
determined at various concentrations of tRNA while maintaining ATP and His constant at
2.5 mM and 75 µM, respectively (Fig. 2D). The KM and kcat values were determined to be
1.5 µM and 0.85 s−1, respectively. The same values reported for E. coli HisRS are 1.4 µM
and 2.6 s−1, respectively.12
Screening Chemical Compounds against the Activity of P. aeruginosa HisRS

Author Manuscript

Initially, to achieve the maximum signal in the SPAs, all nonenzymatic components of the
aminoacylation reaction were individually titrated into the assay to determine the saturating
concentration of each (data not shown). Next, tRNA was titrated into the assay to ensure that
the assay was within the linear region of the reaction detection time and to determine the
concentration of tRNA to be used in the screening assays (Suppl. Fig. S2). Finally, HisRS
was titrated into the assay to determine the enzyme concentration yielding maximum
sensitivity to enzymatic inhibition (Fig. 2A). From these data, a HisRS concentration of 0.2
µM was chosen for screening reactions. Using this optimized assay, the activity of HisRS in
the aminoacylation assay was screened against two chemical compound libraries. One
contained an 800-compound collection of natural products, including simple and complex
oxygen heterocycles, alkaloids, sesquiterpenes, diterpenes, pentacyclic triterpenes, and
sterols from Microsource Discovery Systems (Gaylordsville, CT). The second collection
included 890 low-molecular-weight, druglike molecules with scaffolds found in antiseptic
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agents with antibacterial, antifungoid, and antimicrobial activities from TimTec LLC
(Newark, DE). The SPA detects the ability of HisRS to aminoacylate tRNAHis and, in the
presence of a chemical compound, to measure the effect of the compound on the activity of
HisRS. Chemical compounds were dissolved in 100% DMSO, resulting in final DMSO
concentrations in screening assays of 4%; therefore, the ability of P. aeruginosa HisRS to
function in the presence of increasing amounts of DMSO was determined. No decrease of
activity was observed in aminoacylation assays containing up to 10% DMSO (Suppl. Fig.
S3). Initial screening assays contained chemical compounds at a concentration of 132 µM
and were carried out as single point assays. Compounds observed to inhibit at least 50% of
enzymatic activity were reassayed in triplicate. These assays resulted in 15 confirmed hit
compounds, all from the synthetic compound library. The IC50 values for the confirmed hit
compounds were determined and as a group ranged from 2 to 45.1 µM (Suppl. Table S2, Fig.
3).
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Microbiological Assays
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The 15 hit compounds were tested in broth microdilution assays to determine MICs against
a panel of nine pathogenic bacteria, including efflux pump mutants of E. coli and P.
aeruginosa and a hypersensitive strain of P. aeruginosa (Suppl. Tables S2 and S3). Despite
the similarity in the IC50 values of the compounds, the ability to inhibit bacterial growth in
cultures varied considerably. Based on compound scaffold similarity and broad-spectrum
activity against both Gram-positive and Gram-negative pathogens, four of the compounds,
BT02C02, BT02D04, BT08E04, and BT09C11 (Fig. 4), were selected for further analysis.
BT02C02 inhibited the growth of the S. pneumoniae and E. coli efflux pump mutant at 16
µg/mL, S. aureus at 32 µg/mL, and E. faecalis and H. influenzae at 64 µg/mL. BT02D04
inhibited the growth of S. pneumoniae and S. aureus at 32 µg/mL, and H. influenzae, the E.
coli efflux pump mutant, and the P. aeruginosa hypersensitive strain at 64 µg/mL. BT08E04
inhibited the growth of E. faecalis, S. pneumoniae, and S. aureus at 32 µg/mL, and H.
influenzae and the P. aeruginosa hypersensitive strain at 64 µg/mL. BT09C11 inhibited the
growth of the E. coli efflux pump mutant, S. aureus, H. influenzae, S. pneumoniae, E.
faecalis, and the P. aeruginosa hypersensitive strain at 4, 8, 16, 16, 32, and 32 µg/mL,
respectively. None of the four compounds were observed to inhibit the growth of wild-type
E. coli or wild-type P. aeruginosa at concentrations below 128 µg/mL.
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Next, time-kill studies were performed using the four compounds BT02C02, BT02D04,
BT08E04, and BT09C11 to determine the mode of inhibition of bacterial growth in cultures.
Based on MIC results, all compounds were tested against cultures of S. aureus, a Grampositive pathogen. BT02D04, BT08E04, and BT09C11 were also tested against cultures
containing the P. aeruginosa hypersensitive strain. However, because of the elevated MIC
observed for BT02C02 against the hypersensitive strain of P. aeruginosa, it was tested
against H. influenzae, another Gramnegative pathogen. All cultures contained compounds at
four times the MIC, and samples were analyzed between 0 and 24 h. All four compounds
were shown to be bacterio-static against the pathogens tested (Fig. 5). In these tests, the
bacteria were observed to have constant growth in the presence of compound but a decrease
of 1–5 log10 colony-forming units (CFU) compared with the control during the first 6 h.
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Antibiotic therapies that specifically target bacterial translation could potentially be toxic to
human cells, given that both human cytoplasmic and mitochondria HisRS are contained
within the human cell, and each share a modest level of amino acid sequence homology and
biochemical similarity with the bacterial HisRS. MTT assays were performed to examine
whether the hit compounds BT02C02, BT02D04, BT08E04, and BT09C11 were cytotoxic
to human cells. HEK293 cells were treated with 25–400 µg/mL of each compound
separately for 24 h under standard tissue culture conditions in triplicate. BT02C02 and
BT09C11 were not observed to be toxic to cells at any concentration tested (Fig. 6A). Some
toxic effects were observed at higher concentrations for BT02D04 and BT08E04 in the
HEK293 cell cultures (Fig. 6C,D), with the CC50 values for both these two compounds near
200 µg/mL. However, even at these inhibitory concentrations, the cytotoxic potential was
60,000-fold lower when compared with the control staurosporine (Fig. 6B). The MIC for
BT02D04 and BT08E04 at 32 and 64 µg/mL for susceptible bacteria is three to six times
lower than the CC50 of the toxicity studies. The other two compounds, BT02C02 and
BT09C11, were observed to have MICs ranging from 4 to 64 µg/mL against susceptible
bacteria and were not observed to be toxic in the cell cultures up to 400 µg/mL. This level of
difference between MIC and CC50 is advantageous in the development of potential
antimicrobial agents. These results indicate that all four compounds may be amenable to
development as therapeutics.
Mechanism of Action
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aaRSs in general have three substrates: tRNA, ATP, and the amino acid. ATP and His are
small molecules similar in size to the compounds tested, and both have binding sites in the
active site region of the synthetase. Since blocking the binding site of one of these substrates
would be a possible mechanism of action of an inhibitor, the ability of each of the four
compounds to compete for binding with each of these substrates was determined (Suppl.
Table S4). The mechanism of inhibition with respect to ATP was determined using the tRNA
aminoacylation assay to determine IC50 values at various ATP concentrations (25, 50, 100,
250, 500, and 1000 µM), while holding the concentration of the amino acid at 100 µM. To
determine the mechanism of inhibition with respect to His, the same assay was used, except
that ATP was held constant at a saturating concentration (2.5 mM) and the IC50 was
determined at different concentrations of His (25, 50, 100, 200, and 300 µM). The IC50
values for BT02C02 remained constant at varying concentrations of ATP. However, an
increase was observed at increasing concentrations of His. An increase in the IC50 as the
concentration of the substrate increases is characteristic of a competitive inhibitor.26 The
IC50 for BT09C11 remained constant at varying concentrations of ATP, but was observed to
decrease as the concentration of His was increased, which is characteristic of an
uncompetitive inhibitor.26 The IC50 values for both BT02D04 and BT08E04 remained
constant at all concentrations of both ATP and His, which is characteristic of a
noncompetitive inhibitor.26 These results lead us to conclude that BT02C02 may inhibit
HisRS by direct competition with the amino acid, while BT02D04, BT08E04, and BT09C11
inhibit the function of the enzyme by a different mechanism.
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Discussion
As reports of resistant bacteria continue to increase, there is a need for the discovery of new
antibacterial agents with different modes of action than those of the currently marketed
antibiotics. The aaRSs are ideal targets for development of new antibacterial agents for a
number of reasons.5 First, they play a crucial role in protein biosynthesis and are vital for
cell viability and growth. Second, the aaRS proteins from prokaryotic origins are conserved
in primary structure yet sufficiently divergent from their eukaryotic homologs to make them
suitable targets for development of selective broad-spectrum antibacterial agents. Finally, the
crystal structures of many of the aaRSs have been solved and provide useful information for
rational drug design.
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His is one of the more functional amino acids in proteins and often is a catalytic residue or a
ligand for metal binding. For these reasons, a high degree of accuracy for attaching the
correct amino acid to the cognate tRNA is required. Studies have shown that RNAi silencing
to partially suppress HisRS expression had a profound effect on the growth of a bloodstream
form of Trypanosoma brucei, decreasing growth by a factor of >103 at day 4 compared with
the normal cells.8 Even with the knowledge of the importance of HisRS, there has been little
work to develop inhibitors of this enzyme, and most of the published data are focused on the
crystal structures, fidelity mechanism, and tRNA recognition.
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In the present work, SPA technology was used to develop a screen for inhibitors of the
activity of P. aeruginosa HisRS. The screening assays were robust and resulted in Z′ and Z
factors of approximately 0.61 and 0.52, respectively, across all plates. The signal-tobackground ratio of the DMSO-positive controls to the EDTA-negative controls was
approximately 5:1. From almost 1700 compounds, 15 compounds (exclusively from the
synthetic compound library) were identified that inhibited the activity of P. aeruginosa
HisRS. Four of the compounds, BT02C02, BT02D04, BT08E04, and BT09C11, inhibited
the activity of HisRS with IC50 values of 4.4, 9.7, 14.1, and 11.3 µM, respectively, and
exhibited promising MICs against both Gram-positive and Gram-negative bacteria. Time-kill
studies indicated that all four compounds were bacteriostatic. This would be the expected
mode of action for compounds that inhibit the activity of an aaRS, since inhibition of the
aminoacylation activity mimics starvation for amino acids by lowering the ratio of charged
to uncharged tRNA, and induces the stringent response resulting in static bacterial growth.27
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Each of the four compounds contains a carboxamide group (Fig. 4), which is present in
some well-known antibiotics, as has been noted previously.13 Tetracycline contains a
carboxamide as a side chain. However, in all four of these hit compounds this motif serves
as part of the core compound. Compound 08E04 also contains a nitrofuran group. Many
compounds containing nitrofurans have been shown to have antibacterial activity and are
included in a class of synthetic antibiotics, including furazolidone, furaltadone,
nitrofurantoin, and nitrofurazone,28 that are active against certain Gram-positive
staphylococci and streptococci, but inactive against P. aeruginosa. BT09C11 was observed to
have the best broad-spectrum activity and lowest MIC values of the four hit compounds.
This compound contains a sulfonamide group, which has been shown to have antibacterial
activity as a functional group in other compounds. Some compounds containing a
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sulfonamide group also have been shown to act as a competitive inhibitor of the enzyme
dihydropteroate synthase (DHPS), which is involved in folate synthesis.29 With this in mind,
this compound may have more than one mode of inhibitory activity. We searched the
PubChem BioAssay Database for biological activity and found no biological information
associated with any of the four hit compounds.
In an era of MDR bacteria, compounds with a different mechanism of action, or with
different binding sites, would be advantageous. As observed in the competition assays
(Suppl. Table S4), as a whole these compounds do not interfere with binding of ATP or the
amino acid substrates. This indicates that the compound interactions with HisRS occur at
sites other than within the active site for aminoacylation. Structure–activity relationship
(SAR) studies will need to be conducted to enhance these interactions, resulting in increased
potency while maintaining low levels of toxicity to eukaryotic cells.
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Figure 1.
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Alignment of amino acid sequence of P. aeruginosa HisRS with homologs. The protein
sequences were downloaded from the National Center for Biotechnology Information
(NCBI). Ec, E. coli; Pa, P. aeruginosa; Sa, S. aureus; Tth, T. thermophilus. Accession
numbers for HisRS protein sequences of E. coli, P. aeruginosa, S. aureus, and T.
thermophilus are KGL70691, WP_003092797, CAD80177, and YP_143978, respectively.
Sequence alignments were performed using Vector NTI Advance 11.5.4 (Invitrogen).
Identical residues are indicated by white letters on black background, while similar
sequences are black letters on gray background. The three structural motifs I, II, and III and
the functional motifs HisA and HisB are indicated. Amino acids that interact with His (●),
ATP (▲), and tRNA (*) are indicated above the aligned residues.
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Figure 2.

Author Manuscript

Enzyme activity and determination of kinetic parameters for interactions of P. aeruginosa
HisRS with His, ATP, and tRNAHis. (A) Titration of P. aeruginosa HisRS into the
aminoacylation assay to determine optimal enzyme screening concentrations. Initial
velocities for the interaction of P. aeruginosa HisRS with His (B), ATP (C), and tRNAHis (D)
were determined, and the data were fit to a Michaelis–Menten steady-state model using
XLfit 5.3 (IDBS) to determine the (E) kinetic parameters KM and kcat.
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Figure 3.
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Determination of the IC50 of selected hit compounds against the activity of P. aeruginosa
HisRS. The IC50 values for the inhibitory activity of (A) BT02C02, (B) BT02D04, (C)
BT08E04, and (D) BT09C11 were 4.4, 9.7, 14.1, and 11.3 µM, respectively. The IC50 values
were determined with the test compounds serially diluted from 200 to 0.4 µM in
aminoacylation assays containing P. aeruginosa HisRS at 0.1 µM. The concentrations of ATP
and His were held constant at 2.5 and 75 µM, respectively.
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Figure 4.

Chemical structure of the hit compounds: (A) BT02C02, (B) BT02D04, (C) BT08E04, and
(D) BT09C11. All structures were drawn using ChemDraw Professional 16.0.
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Figure 5.
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Time-kill kinetics against MIC determined bacterial targets: (A) P. aeruginosa hypersensitive
strain, (B) H. influenzae, and (C) S. aureus. Compounds were added to bacterial cultures at
4× MIC. Samples were analyzed by plating and determination of CFU at 0, 2, 4, 6, and 24 h.
Filled circles (●) represent control cultures grown in the absence of compound, filled
squares (■) represent cultures containing BT02C02, open circles (○) represent cultures
containing BT02D04, filled triangles (▲) represent cultures containing BT08E04, and
diamonds (◆) represent cultures containing BT09C11.
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Figure 6.
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Determination of the compound toxicity in mammalian cell cultures. MTT assays were
performed with the indicated dose of drug for 24 h under standard tissue culture conditions,
as described in Materials and Methods. (A) There was no toxicity observed for compounds
BT02C02 (solid column) and BT09C11 (hatched column) up to 400 µg/mL. The control (B)
staurosporine was serial diluted in assays from 1 to 0.001 µg/mL to determine CC50 (0.003
µg/mL). In assays containing 25, 50, 100, 200, 300, and 400 µg/mL, the CC50 values for
both compounds (C) BT02D04 and (D) BT08E04 were determined to be 200 µg/mL. “%
Positive” indicates the percent of growth of cell cultures containing compound observed
relative to growth of cell cultures where only DMSO was added to the assay in the absence
of compound. The data points represent an average value for assays carried out in triplicate.
The curve fits and CC50 values were determined using the sigmoidal dose–response model
in XLfit 5.3 (IDBS) as part of Microsoft Excel.
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